Return to Clinical Trials

Intravenous Administration In Combination With Gemcitabine - United Kingdom

In June 2009, Oncolytics announced positive results of its U.K. trial using intravenous administration of REOLYSIN® in combination with gemcitabine. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and/or clinical response and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with gemcitabine. Secondary objectives included the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

See related press releases and documents:

A phase-I study of the combination of intravenous reolysin (wild-type reovirus) and gemcitabine (REO-GEM) in patients with advanced cancer

June 1, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

March 25, 2009 - Oncolytics Biotech® Inc. Completes Enrolment in Combination REOLYSIN®/Gemcitabine Trial

June 11, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Gemcitabine Trial

January 3, 2007 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Gemcitabine